SpringerLink
Log in

Renal and Nonrenal Clearance of Clodronate in Patients with Malignancy and Renal Impairment

  • Original Research Article
  • Published:
Drug Investigation Aims and scope Submit manuscript

Summary

The short term pharmacokinetics of the bisphosphonate clodronate were studied in 20 patients with tumour-mediated bone disease and a wide range of renal function (creatinine clearance 13 to 112 ml/min; mean 54.8 ml/min). Clodronate 300mg was given as a single intravenous infusion over 2 hours and the concentration of drug in serum and urine was measured at intervals for 24 hours after the start of the infusion. The total clearance was 86.6 ± 7.4 ml/min (mean ± SEM), with an apparent renal clearance of 41.0 ± 4.3 ml/min, and thus a nonrenal clearance of 45.6 ± 5.2 ml/min. The range of nonrenal clearance was as great as that of renal function. Both renal and total clearance showed a significant positive correlation with renal function, as judged by endogenous creatinine clearance (r = 0.66, p = 0.002 and r = 0.62, p = 0.004, respectively). The slope of the regression line of renal clearance on creatinine clearance was 0.46, but renal clearance of clodronate exceeded creatinine clearance in 7 patients, 6 of whom had marked renal impairment. Neither nonrenal clearance nor half-life correlated significantly with renal function.

We conclude that there is no need to adjust the dose interval of clodronate in patients with renal impairment, but that the dose of clodronate should be reduced in the presence of markedly impaired renal function. However, the range of nonrenal clearance is high, so that difficulties arise in dose adjustments made on the basis of renal function alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bonjour JP, Rizzoli R. Pathophysiological aspects and therapeutic approaches of tumoral osteolysis and hypercalcaemia. Recent Results in Cancer Research 116: 29–39, 1989

    Article  PubMed  CAS  Google Scholar 

  • Boonekamp PM, van der Wee Pals LJA, van Wijk-van Lennep MML, Thesingh CW, Bijvoet OLM. Two models of action of bisphosphonates on osteoclastic resorption of mineralised matrix. Bone and Mineral 1: 27–39, 1986

    PubMed  CAS  Google Scholar 

  • Bisaz S, Jung A, Fleisch H. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clinical Science and Molecular Medicine 54: 265–272, 1978

    PubMed  CAS  Google Scholar 

  • Conrad KA, Lee SM. Clodronate kinetics and dynamics. Clinical Pharmacology and Therapeutics 30: 114–120, 1981

    Article  PubMed  CAS  Google Scholar 

  • Daley-Yates PT, Gifford LA, Hoggarth CR. Assay of 1-hydroxy-3-aminopropylidene-1, 1-biphosphonate and related biphosphonates in human urine and plasma by high performance ion chromatography. Journal of Chromatography and Biomedical Applications 490: 329–338, 1989

    Article  CAS  Google Scholar 

  • Delmas PD, Charhon S, Chapuy MC, Vignon E, Briancon D, Eduoard C, Meurnier PJ. Long-term effects of dichloromethylene and diphosphonate on skeletal lesions in multiple myeloma. Metabolic Bone Disease and Related Research 4: 163–168, 1982

    Article  CAS  Google Scholar 

  • Elomaa I, Blomqvist C, Grohn P. Long term controlled trial with diphosphonate in patients with osteolytic metastases. Lancet 1: 146–149, 1983

    Article  PubMed  CAS  Google Scholar 

  • Endele. Boehringer Mannheim internal procedures for clodronate serum and urine detection. Mannheim 1989

  • Fleisch H. Bisphosphonates: mechanisms of action and clinical applications. In Peck (Ed.) Bone and Mineral Research, vol. 1, pp. 319–357, Excerpta Medica, Amsterdam 1983

    Google Scholar 

  • Flesch G, Hauffe SA. Determination of the biphosphonate pamidronate disodium in urine by pre-column derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection. Journal of Chromatography and Biomedical Applications 489: 446–451, 1989

    Article  CAS  Google Scholar 

  • Kanis JA, Cundy T, Heynen G, Russell RGG. The pathophysiology of hypercalcaemia. Metabolic Bone Disease and Related Research 2: 151–159, 1980

    Article  Google Scholar 

  • Kanis JA, McCloskey EV, O’Rourke N, Vasikaran S, Eyres K, et al. Future opportunities for bisphosphonates in osteoporosis. In Christiansen & Overgaard (Eds) Osteoporosis, Third International Symposium on Osteoporosis, Copenhagen, Vol. 3, pp. 1963–1967, 1990

  • Miller SC, Jee WSS. The effect of dichlormethylene-diphosphonate, a pyrophosphate analogue, on bone and bone cell structure in the growing rat. Anatomical Records 193: 439–462, 1979

    Article  CAS  Google Scholar 

  • Monkkonen J. A one year follow-up study of the distribution of 14C-clodronate in mice and rats. Pharmacology and Toxicology 62: 51–53, 1988

    Article  PubMed  CAS  Google Scholar 

  • Paterson AD, Kanis JA, Cameron EC, Douglas DL, Beard DJ, et al. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. British Journal of Haematology 54: 121–132, 1983

    Article  PubMed  CAS  Google Scholar 

  • Paterson AHG, Powles TJ, Kanis JA, McCloskey EV, Hanson J, et al. Oral clodronate decreases skeletal morbidity in patients with bone metastases for breast cancer. A double blind controlled trial. Journal of Clinical Oncology 11: 59–65, 1993

    PubMed  CAS  Google Scholar 

  • Pentikainen PJ, Elomaa J, Nurmi AK, Karkainen S. Pharmacokinetics of clodronate in patients with metastatic breast cancer. International Journal of Clinical Pharmacology 27: 222–228, 1989

    CAS  Google Scholar 

  • Rowe DJ, Etre LA. Uptake of a fluorinated bisphosphonate by cultured bones. Bone 9: 297–301, 1988

    Article  PubMed  CAS  Google Scholar 

  • Sato M, Grasser W, Endo N, Akins R, Simmons H, et al. Alendronate localization in rat bone and effects on osteoclast ultrastructure. Journal of Clinical Investigation 88: 2095–2105, 1991

    Article  PubMed  CAS  Google Scholar 

  • Schenk R, Merz WA, Muhlbauer E, Russell RGG, Fleisch H. Effects of EHDP and Cl MDP on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcified Tissue International 11: 196–214, 1973

    Article  CAS  Google Scholar 

  • Siris ES, Hyman GA, Canfield RE. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. American Journal of Medicine 74: 401–406, 1983

    Article  PubMed  CAS  Google Scholar 

  • Stegemann H, Stalder K. Determinations of hydroxyproline. Clinica Chimica Acta 18: 267–273, 1967

    Article  CAS  Google Scholar 

  • Stutzer A, Trechsel U, Fleisch H. Effect of bisphosphonates on osteoclast number and bone resorption in the rat. Journal of Bone and Mineral Research 2 (Suppl. 2): 266, 1987

    Google Scholar 

  • Troehler U, Bonjour JP, Fleisch H. Renal secretion of diphosphonates in rats. Kidney International 8: 6–13, 1975

    Article  PubMed  CAS  Google Scholar 

  • Urwin GH, Yates AJP, Gray RES, Hamdy NAT, McCloskey EV, et al. Treatment of hypercalcaemia of malignancy with intravenous clodronate. Bone 8 (Suppl.): 43–51, 1987

    Google Scholar 

  • Wiedmer WH, Zbinden AM, Trechsel U, Fleisch H. Ultrafiltrability and Chromatographie properties of pyrophosphate, 1-hydroxyethylidene-1, 1-bisphosphonate, and dichloromethylenebisphosphonate in aqueous buffers and in human plasma. Calcified Tissue International 35: 397–400, 1983

    Article  PubMed  CAS  Google Scholar 

  • Yakatan GJ, Poynor WJ, Talbert RL, Floyd BF, Slough CL, et al. Clodronate kinetics and bioavailability. Clinical Pharmacology and Therapeutics 31: 402–410, 1982

    Article  PubMed  CAS  Google Scholar 

  • Yates AJP, Percival RC, Gray RES, Atkins RM, Urwin GH, et al. Intravenous clodronate in the treatment and retreatment of Paget’s disease of bone. Lancet 1: 1474–1477, 1985

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, Medical School, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, England

    N. P. O’Rourke, E. V. McCloskey &  J. A. Kanis

  2. Boehringer Mannheim, Mannheim, Germany

    G. Neugebauer

Authors
  1. N. P. O’Rourke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. V. McCloskey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Neugebauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. A. Kanis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Rourke, N.P., McCloskey, E.V., Neugebauer, G. et al. Renal and Nonrenal Clearance of Clodronate in Patients with Malignancy and Renal Impairment. Drug Invest 7, 26–33 (1994). https://doi.org/10.1007/BF03257396

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03257396

Keywords

Search

Navigation